0001104659-26-059752
SEC filingMilestone Pharmaceuticals reported its first quarter of product revenue from CARDAMYST, but operating losses and cash outflows widened year-over-year as the Company advanced commercialization efforts without yet achieving scale.
Milestone recognized $238.0K in product revenue during Q1 FY2026 — its first reported revenue from CARDAMYST following FDA approval and U.S. commercial launch. This milestone reflects execution against the Company’s core strategic objective: transitioning from development-stage biopharma to a commercial organization. As noted in management commentary, the Company is now generating product revenues, though it expects operating losses and negative cash flows from operations to continue for the foreseeable future.
Gross profit totaled $224.0K, resulting in a gross margin of 94.1%. This high margin is attributable to de minimis cost of goods sold in the quarter, consistent with inventory carrying a zero-cost basis from pre-approval manufacturing — a fact disclosed in the financial statements. While indicative of favorable unit economics at launch, management has not represented this margin as sustainable or representative of long-term cost structure, given anticipated capitalization of production costs and potential inventory write-downs if quality specifications are unmet.
Net cash used in operating activities was -$16.1M, compared to -$14.0M in Q1 FY2025. Capital expenditures were $45K, up from $6K year-over-year, reflecting modest infrastructure investment. Free cash flow was -$16.1M. Management states explicitly that the Company has incurred operating losses and negative operating cash flows since inception and expects to incur additional costs in connection with commercialization — a forward-looking statement grounded in the business context packet and fully supported by the reported results.
The Company reiterates that although it is now generating product revenue, operating losses and negative cash flows from operations will continue. This outlook is consistent with the financial performance observed and with disclosures regarding the inherent uncertainty in estimating future royalty payments, timing of commercial production, and patent duration — all factors influencing long-term financial modeling but not quantifiable at this stage.